Skip to NavigationSkip to content


Cell Therapy signs £12.5 million licensing deal with Daiichi Sankyo for heart failure treatment

UK-based Cell Therapy on Tuesday said it has signed a £12.5 million licensing deal with Japan’s Daiichi Sankyo (TYO: 4568) for its heart failure treatment, Heartcel. 

Under the terms of the deal Daiichi Sankyo will undertake all development, regulatory and commercial activities for Heartcel in Japan. CTL will also be eligible to receive additional milestone payments and royalties. 

Drug & R&D Portfolio Valuation Forum

Pharmaceutical Portfolio & Lifecycle Management

euroPLX 51 Limassol (Cyprus)

ChinaBio Partnering Forum 2013

BIO-Europe Spring 2013

Licensing for Pharmaceuticals and Biopharmaceuticals

BIO-Europe® 2012

Informa Life Sciences' Lifecycle Management of the eCTD

BioPharm America™ 2012

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches